Viral load and short-term natural history of type-specific oncogenic human papillomavirus infections in a high-risk cohort of midadult women

International Journal of Cancer

Volumn 134, Issue 8, 2014, Pages 1889-1898

  Winer, Rachel L ^a   Xi, Long Fu ^a   Shen, Zhenping ^a   Stern, Joshua E ^a   Newman, Laura ^a   Feng, Qinghua ^a   Hughes, James P ^a   Koutsky, Laura A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

epidemiology; human papillomavirus; persistence; viral load; women

Indexed keywords

EPIDEMIOLOGY; HUMAN PAPILLOMAVIRUS; PERSISTENCE; VIRAL LOAD; WOMEN;

ADULT; AGED; COHORT STUDIES; DNA, VIRAL; FEMALE; HUMANS; MIDDLE AGED; ONCOGENIC VIRUSES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; QUESTIONNAIRES; RISK; SEXUAL BEHAVIOR; SEXUAL PARTNERS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; VIRAL LOAD;

EID: 84893764384     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28509     Document Type: Article

References (50)

1. Grant LA, Dunne EF, Chesson H, et al. Considerations for human papillomavirus (HPV) vaccination of mid-adult women in the United States. Vaccine 2011; 29: 2365-70.
2. Burchell AN, Winer RL, de Sanjose S, et al. Chapter 6: epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006; 24 Suppl 3: S52-61. (Pubitemid 44293018)
3. Moscicki AB, Schiffman M, Kjaer S, Villa LL,. Chapter 5: updating the natural history of HPV and anogenital cancer. Vaccine 2006; 24 Suppl 3: S42-51. (Pubitemid 44308674)
4. Winer RL, Hughes JP, Feng Q, et al. Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol Biomarkers Prev 2011; 20: 699-707.
5. Gravitt PE,. Evidence and impact of human papillomavirus latency. Open Virol J 2012; 6: 198-203.
6. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 2012; 137: 516-42.
7. Moyer VA,. Screening for cervical cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 2012; 156: 880-91.
8. Carter JJ, Koutsky LA, Wipf GC, et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 1996; 174: 927-36. (Pubitemid 26357453)
9. Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000; 181: 1911-9. (Pubitemid 30416152)
10. Strickler HD, Schiffman MH, Shah KV, et al. A survey of human papillomavirus 16 antibodies in patients with epithelial cancers. Eur J Cancer Prev 1998; 7: 305-13. (Pubitemid 28473982)
11. Winer RL, Hughes JP, Feng Q, et al. Prevalence and risk factors for oncogenic human papillomavirus infections in high-risk mid-adult women. Sex Transm Dis 2012; 39: 848-56.
12. Winer RL, Harris TG, Xi LF, et al. Quantitative human papillomavirus 16 and 18 levels in incident infections and cervical lesion development. J Med Virol 2009; 81: 713-21.
13. Xi LF, Hughes JP, Castle PE, et al. Viral load in the natural history of human papillomavirus type 16 infection: a nested case-control study. J Infect Dis 2011; 203: 1425-33.
14. Josefsson AM, Magnusson PK, Ylitalo N, et al. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 2000; 355: 2189-93. (Pubitemid 30394325)
15. Ylitalo N, Sorensen P, Josefsson AM, et al. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet 2000; 355: 2194-8. (Pubitemid 30394326)
16. Moberg M, Gustavsson I, Gyllensten U,. Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ. Int J Cancer 2004; 112: 854-9. (Pubitemid 39435271)
17. Moberg M, Gustavsson I, Wilander E, et al. High viral loads of human papillomavirus predict risk of invasive cervical carcinoma. Br J Cancer 2005; 92: 891-4. (Pubitemid 40462636)
18. Schlecht NF, Trevisan A, Duarte-Franco E, et al. Viral load as a predictor of the risk of cervical intraepithelial neoplasia. Int J Cancer 2003; 103: 519-24. (Pubitemid 36020228)
19. Munoz N, Castellsague X, de Gonzalez AB, et al. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006; 24S3: S1-S10. (Pubitemid 44293019)
20. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens-Part B: biological agents. Lancet Oncol 2009; 10: 321-2.
21. Nielsen A, Kjaer SK, Munk C, et al. Persistence of high-risk human papillomavirus infection in a population-based cohort of Danish women. J Med Virol 2010; 82: 616-23.
22. Molano M, Van den Brule A, Plummer M, et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003; 158: 486-94. (Pubitemid 37022847)
23. Bae J, Seo SS, Park YS, et al. Natural history of persistent high-risk human papillomavirus infections in Korean women. Gynecol Oncol 2009; 115: 75-80.
24. Carcopino X, Henry M, Mancini J, et al. Two years outcome of women infected with high risk HPV having normal colposcopy following low-grade or equivocal cytological abnormalities: are HPV16 and 18 viral load clinically useful predictive markers? J Med Virol 2012; 84: 964-72.
25. Dalstein V, Riethmuller D, Pretet JL, et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer 2003; 106: 396-403. (Pubitemid 36870403)
26. Lai CH, Chao A, Chang CJ, et al. Host and viral factors in relation to clearance of human papillomavirus infection: a cohort study in Taiwan. Int J Cancer 2008; 123: 1685-92.
27. Munoz JP, Gonzalez C, Parra B, et al. Functional interaction between human papillomavirus type 16 E6 and E7 oncoproteins and cigarette smoke components in lung epithelial cells. PloS one 2012; 7: e38178.
28. Constandinou-Williams C, Collins SI, Roberts S, et al. Is human papillomavirus viral load a clinically useful predictive marker? A longitudinal study. Cancer Epidemiol Biomarkers Prev 2010; 19: 832-7.
29. Ramanakumar AV, Goncalves O, Richardson H, et al. Human papillomavirus (HPV) types 16, 18, 31, 45 DNA loads and HPV-16 integration in persistent and transient infections in young women. BMC Infect Dis 2010; 10: 326.
30. Xi LF, Hughes JP, Edelstein ZR, et al. Human Papillomavirus (HPV) type 16 and type 18 DNA loads at baseline and persistence of type-specific infection during a 2-year follow-up. J Infect Dis 2009; 200: 1789-97.
31. Trottier H, Ferreira S, Thomann P, et al. Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res 2010; 70: 8569-77.
32. Kovacic MB, Castle PE, Herrero R, et al. Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res 2006; 66: 10112-9. (Pubitemid 44672065)
33. Wentzensen N, Gravitt PE, Long R, et al. Human papillomavirus load measured by Linear Array correlates with quantitative PCR in cervical cytology specimens. J Clin Microbiol 2012; 50: 1564-70.
34. Xi LF, Koutsky LA, Castle PE, et al. Relationship between cigarette smoking and human papilloma virus types 16 and 18 DNA load. Cancer Epidemiol Biomarkers Prev 2009; 18: 3490-6.
35. Ho GYF, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 423-8. (Pubitemid 28135669)
36. Hildesheim A, Schiffman MH, Gravitt PE, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994; 169: 235-40. (Pubitemid 24045578)
37. Giuliano AR, Sedjo RL, Roe DJ, et al. Clearance of oncogenic human papillomavirus (HPV) infection: effect of smoking (United States). Cancer Causes Control 2002; 13: 839-46. (Pubitemid 35305203)
38. Richardson H, Abrahamowicz M, Tellier PP, et al. Modifiable risk factors associated with clearance of type-specific cervical human papillomavirus infections in a cohort of university students. Cancer Epidemiol Biomarkers Prev 2005; 14: 1149-56. (Pubitemid 40656460)
39. Schmeink CE, Melchers WJ, Siebers AG, et al. Human papillomavirus persistence in young unscreened women, a prospective cohort study. PLoS One 2011; 6: e27937.
40. Maucort-Boulch D, Plummer M, Castle PE, et al. Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology. Int J Cancer 2010; 126: 684-91.
41. Syrjanen S, Shabalova I, Petrovichev N, et al. Factors predicting persistence of high-risk human papillomavirus (HPV) infections in women prospectively followed-up in three New Independent States (NIS) of the former Soviet Union. Eur J Gynaecol Oncol 2005; 26: 491-8. (Pubitemid 41585929)
42. Sycuro LK, Xi LF, Hughes JP, et al. Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students. J Infect Dis 2008; 198: 971-8.
43. Munoz N, Hernandez-Suarez G, Mendez F, et al. Persistence of HPV infection and risk of high-grade cervical intraepithelial neoplasia in a cohort of Colombian women. Br J Cancer 2009; 100: 1184-90.
44. Sammarco ML, Del Riccio I, Tamburro M, et al. Type-specific persistence and associated risk factors of human papillomavirus infections in women living in central Italy. Eur J Obstet Gynecol Reprod Biol 2013; 168: 222-26.
45. Kalra R, Singh SP, Savage SM, et al. Effects of cigarette smoke on immune response: chronic exposure to cigarette smoke impairs antigen-mediated signaling in T cells and depletes IP3-sensitive Ca(2+) stores. J Pharmacol Exp Ther 2000; 293: 166-71. (Pubitemid 30180936)
46. Sopori M,. Effects of cigarette smoke on the immune system. Nat Rev Immunol 2002; 2: 372-7. (Pubitemid 37328760)
47. Zeidel A, Beilin B, Yardeni I, et al. Immune response in asymptomatic smokers. Acta Anaesthesiol Scand 2002; 46: 959-64. (Pubitemid 34953680)
48. Barton SE, Maddox PH, Jenkins D, et al. Effect of cigarette smoking on cervical epithelial immunity: a mechanism for neoplastic change? Lancet 1988; 2: 652-4.
49. Poppe WA, Ide PS, Drijkoningen MP, et al. Tobacco smoking impairs the local immunosurveillance in the uterine cervix. An immunohistochemical study. Gynecol Obstet Invest 1995; 39: 34-8.
50. Jiang M, Baseman JG, Koutsky LA, et al. Sequence variation of human papillomavirus type 16 and measurement of viral integration by quantitative PCR. J Clin Microbiol 2009; 47: 521-6.